Tepotinib in METex14 skipping alteration NSCLC

Tepotinib in METex14 skipping alteration NSCLC

VJOncology

1 year
140 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Enriqueta Felip, MD, PhD, of Vall dHebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations. Dr Felip covers the rationale behind the use of this drug, as well as the cohort and promising results of the study. This interview was recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL.
Up Next Autoplay
Zomas Question 2
Zomas Question 2
Category: Chronic Myelogenous Leukemia
0 Views
admin 1 hour
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
3 Views
ash 4 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 4 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
admin 5 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 5 hours
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 6 hours
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 7 hours
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
4 Views
ash 20 hours
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
6 Views
ash 20 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
4 Views
ash 1 day